Protection against lethal HAdV-4 challenge in STAT1 mice by novel human monoclonal antibodies by Xinyi Zhang, Xinyi Zhang, Zhongge Zhu, Peijie Zhai, Peijie Zhai, Peng Lv, You Yang, Chuanhang Cheng, Busen Wang, Ting Fang, Guanying Zhang, Xiangyang Chi, Jianmin Li, Wei Chen, Yunzhu Dong

Subjects: Get full text

Non-neutralizing monoclonal antibody targeting VP2 EF loop of Coxsackievirus A16 can protect mice from lethal attack via Fc-dependent effector mechanism by Ruixiao Du, Chaoqiang An, Xin Yao, Yiping Wang, Ge Wang, Fan Gao, Lianlian Bian, Yalin Hu, Siyuan Liu, Qiaohui Zhao, Qunying Mao, Zhenglun Liang

Subjects: Get full text

Experience in the use of neutralizing monoclonal antibodies in kidney transplant recipients with COVID-19 by I. G. Kim, M. A. Lysenko, N. F. Frolova, L. Yu. Artyukhina, T. A. Buruleva, A. M. Nikitina, V. E. Vinogradov, E. V. Volodina, V. I. Chervinko, E. V. Kryukov, M. L. Zubkin

Subjects: Get full text

Clinical trials of broadly neutralizing monoclonal antibodies in people living with HIV – a review by Sharana Mahomed, Kayla Pillay, Razia Hassan-Moosa, Bruna P. G. V. Galvão, Wendy A. Burgers, Penny L. Moore, Melissa Rose-Abrahams, Carolyn Williamson, Nigel Garrett

Subjects: “…Broadly neutralizing monoclonal antibodies…”
Get full text

Structural insight into broadening SARS-CoV-2 neutralization by an antibody cocktail harbouring both NTD and RBD potent antibodies by Wenling Jiang, Yanan Jiang, Hui Sun, Tingting Deng, Kunyu Yu, Qianjiao Fang, Huimin Ge, Miaoling Lan, Yanling Lin, Zhongyue Fang, Yali Zhang, Lizhi Zhou, Tingting Li, Hai Yu, Qingbing Zheng, Shaowei Li, Ningshao Xia, Ying Gu

Subjects: Get full text

Neutralizing monoclonal antibodies protect against human adenovirus type 55 infection in transgenic mice and tree shrews by Xinglong Liu, Zhengfeng Li, Xiao Li, Xiaoyan Zhang, Yali Zheng, Wan Su, Ying Feng, Yutong Liu, Weixuan Wu, Xikui Sun, Nana Wang, Xianmiao Ye, Zhichao Zhou, Wenkuan Liu, Jun He, Wei Wang, Linbing Qu, Rong Zhou, Ling Chen, Liqiang Feng

Subjects: “…Human adenovirus type 55; neutralizing monoclonal antibodies; rhesus macaque; targeting sites; mechanism of action…”
Get full text

Pre-exposure prophylaxis of COVID-19 with tixagevimab/cilgavimab (Evusheld) in 63 rituximab-treated patients with ANCA-associated systemic vasculitis: two-year follow-up results by T. V. Beketova, N. O. Levina, Yu. A. Uskova, I. V. Rozanova, M. V. Dubinskaia, S. A. Evdokimova, V. V. Babak, M. F. Beketova, A. V. Devyatkin

Subjects: Get full text

Experience with Tixagevimab and Cilgavimab (Evusheld) in 86 rheumatic patients undergoing anti-B cell therapy with rituximab by T. V. Beketova, N. О. Levina, M. V. Dubinskaia, Yu. A. Uskova, I. V. Rozanova, V. V. Babak, M. F. Beketova, T. N. Krasnova

Subjects: Get full text

Discovery of Synergistic Broadly Neutralizing Antibodies Targeting Non-Dominant Epitopes on SARS-CoV-2 RBD and NTD by Hualong Feng, Zuowei Wang, Ling Li, Yunjian Li, Maosheng Lu, Xixian Chen, Lin Hu, Yi Sun, Ruiping Du, Rongrong Qin, Xuanyi Chen, Liwei Jiang, Teng Zuo

Subjects: “…broadly neutralizing monoclonal antibodies…”
Get full text